Miłosz Parczewski

Prof. Miłosz Parczewski

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
MPMiłosz Parczewski
Miłosz Parczewski
DGDeniz Gökengin
Deniz Gökengin
ASAnn Sullivan
Ann Sullivan
JAJulia de Amo
Julia de Amo
GCGus Cairns
Gus Cairns
JRJürgen Rockstroh
Jürgen Rockstroh
Despite the ambitious global goal to control HIV transmissions by 2030, more than 30% of people with HIV from the WHO European Region show persistent transmissible levels of the virus. Successful introduction of oral pre-exposure prophylaxis (PrEP) has led to significant decreases in new HIV transmissions in some areas of Europe, particularly among men who have sex with men. However, the limited PrEP access or lack of state funding in many European countries underlines the need to increase efforts to make PrEP consistently and equitably available for all individuals in need. The success of modern antiretroviral therapy (ART) is evident throughout the WHO European region, with more than 90% of treated individuals with viral suppression. Remaining barriers to control HIV include disparities in access to testing facilities such as community-based centers, persistently high levels of late diagnosis, delayed linkage to care especially for undocumented migrant populations, and inequalities in access to treatment. Retention in care and maintenance of viral suppression are additional challenges. The ongoing war in Ukraine is causing service disruption for people with HIV. Combating HIV associated stigma and discrimination, particularly in Eastern Europe and Central Asia, seems paramount in removing barriers to testing; new testing strategies, such as emergency room opt-out testing, could enable earlier diagnosis of HIV in transmission groups that have been difficult to reach. This review summarizes the barriers, opportunities, and pathways towards improvement of the HIV response in the WHO European region.

2 February 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
PHPontus Hedberg
Pontus Hedberg
MPMiłosz Parczewski
Miłosz Parczewski
KSKarol Serwin
Karol Serwin
GMGiulia Marchetti
Giulia Marchetti
FBFrancesca Bai
Francesca Bai
PNPontus Nauclér
Pontus Nauclér
Investigating outcomes of hospitalised COVID-19 patients throughout the pandemic is crucial to understand the impact of different SARS-CoV-2 variants. We compared 28-day in-hospital mortality of Wild-type, Alpha, Delta, and Omicron variant infections. Whether the difference in risk by variant varied by age was also evaluated. We conducted a cohort study including patients ≥18 years, hospitalised between 2020 and 02-01 and 2022-10-15 with a SARS-CoV-2 positive test, from nine countries. Variant was classified based on sequenced viruses or from national public metadata. Mortality was compared using the cumulative incidence function and subdistribution hazard ratios (SHR) adjusted for age, sex, calendar time, and comorbidities. Results were shown age-stratified due to effect measure modification (P < 0.0001 for interaction between age and variant). We included 38,585 participants: 19,763 Wild-type, 6387 Alpha, 3640 Delta, and 8795 Omicron. The cumulative incidence of mortality decreased throughout the study period. Among participants ≥70 years, the adjusted SHR (95% confidence interval) for Delta vs. Omicron was 1.66 (1.29–2.13). This estimate was 1.66 (1.17–2.36) for Alpha vs. Omicron, and 1.34 (0.92–1.95) for Wild-type vs. Omicron. These were 1.21 (0.81–1.82), 1.21 (0.68–2.17), and 0.98 (0.53–1.82) among unvaccinated participants. When comparing Omicron sublineages, the aSHR for BA.1 was 1.92 (1.43–2.58) compared to BA.2 and 1.52 (1.11–2.08) compared to BA.5. The herein observed decrease in in-hospital mortality seems to reflect a combined effect of immunity from vaccinations and previous infections, although differences in virulence between SARS-CoV-2 variants may also have contributed. European Union’s Horizon Europe Research and Innovation Programme.

24 February 2022 in JHEP Reports
Verified
Journal Article
Open access
AHAnita Howe
Anita Howe
CRChaturaka Rodrigo
Chaturaka Rodrigo
ECEvan Cunningham
Evan Cunningham
Mark William DouglasMark William Douglas
Mark William Douglas
JDJulia Dietz
Julia Dietz
MMMarianne Martinello
Marianne Martinello
Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission. In this study, we evaluated RAS prevalence and distribution, including novel NS5A RASs and clinical factors associated with RAS selection, among patients who experienced DAA treatment failure. SHARED is an international consortium of clinicians and scientists studying HCV drug resistance. HCV sequence linked metadata from 3,355 patients were collected from 22 countries. NS3, NS5A, and NS5B RASs in virologic failures, including novel NS5A substitutions, were examined. Associations of clinical and demographic characteristics with RAS selection were investigated. The frequency of RASs increased from its natural prevalence following DAA exposure: 37% to 60% in NS3, 29% to 80% in NS5A, 15% to 22% in NS5B for sofosbuvir, and 24% to 37% in NS5B for dasabuvir. Among 730 virologic failures, most were treated with first-generation DAAs, 94% had drug resistance in ≥1 DAA class: 31% single-class resistance, 42% dual-class resistance (predominantly against protease and NS5A inhibitors), and 21% triple-class resistance. Distinct patterns containing ≥2 highly resistant RASs were common. New potential NS5A RASs and adaptive changes were identified in genotypes 1a, 3, and 4. Following DAA failure, RAS selection was more frequent in older people with cirrhosis and those infected with genotypes 1b and 4. Drug resistance in HCV is frequent after DAA treatment failure. Previously unrecognized substitutions continue to emerge and remain uncharacterized. Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.

28 February 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KSKarol Serwin
Karol Serwin
ACAntoine Chaillon
Antoine Chaillon
KSKaja Scheibe
Kaja Scheibe
AUAnna Urbańska
Anna Urbańska
BABogusz Jan Aksak-Wąs
Bogusz Jan Aksak-Wąs
MPMiłosz Parczewski
Miłosz Parczewski
The human immunodeficiency virus (HIV) type 1 A6 variant is dominating in high-prevalence Eastern European countries, with increasing prevalence over the remaining regions of Europe. The recent war in Ukraine may contribute to further introductions of this A6 lineage. Our aim was to model the transmission dynamics of the HIV-1 A6 variant between Poland and Ukraine. HIV-1 A6 partial pol sequences originating from Poland (n = 1185) and Ukraine (n = 653) were combined with publicly available sequences (n = 7675) from 37 other countries. We used maximum likelihood-based tree estimation followed by a bayesian inference strategy to characterize the putative transmission clades. Asymmetric discrete phylogeographic analysis was used to identify the best-supported virus migration events across administrative regions of Poland and Ukraine. We identified 206 clades (n = 1362 sequences) circulating in Poland or Ukraine (63 binational clades, 79 exclusively Polish, and 64 exclusively Ukrainian). Cross-border migrations were almost exclusively unidirectional (from Ukraine to Poland, 99.4%), mainly from Eastern and Southern Ukraine (Donetsk, 49.7%; Odesa, 17.6% regions) to the Central (Masovian, 67.3%; Lodz, 18.2%) and West Pomeranian (10.1%) districts of Poland. The primary sources of viral dispersal were the Eastern regions of Ukraine, long affected by armed conflict, and large population centers in Poland. The Polish outbreak of the A6 epidemic was fueled by complex viralmigration patterns across the country, together with cross-border transmissions fromUkraine. There is an urgent need to include war-displaced people in the national HIV prevention and treatment programs to reduce the further spread of transmission networks.

17 January 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KKKatarzyna Laura Kotfis
Katarzyna Laura Kotfis
KLKacper Lechowicz
Kacper Lechowicz
SDSylwester Drożdżal
Sylwester Drożdżal
Paulina Niedźwiedzka-RystwejPaulina Niedźwiedzka-Rystwej
Paulina Niedźwiedzka-Rystwej
Tomasz K WojdaczTomasz K Wojdacz
Tomasz K Wojdacz
MPMiłosz Parczewski
Miłosz Parczewski
In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO). The clinical course of the disease is unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to acute respiratory distress syndrome (ARDS). It has been shown that pulmonary fibrosis may be one of the major long-term complications of COVID-19. In animal models, the use of spironolactone was proven to be an important drug in the prevention of pulmonary fibrosis. Through its dual action as a mineralocorticoid receptor (MR) antagonist and an androgenic inhibitor, spironolactone can provide significant benefits concerning COVID-19 infection. The primary effect of spironolactone in reducing pulmonary edema may also be beneficial in COVID-19 ARDS. Spironolactone is a well-known, widely used and safe anti-hypertensive and antiandrogenic medication. It has potassium-sparing diuretic action by antagonizing mineralocorticoid receptors (MRs). Spironolactone and potassium canrenoate, exerting combined pleiotropic action, may provide a therapeutic benefit to patients with COVID-19 pneumonia through antiandrogen, MR blocking, antifibrotic and anti-hyperinflammatory action. It has been proposed that spironolactone may prevent acute lung injury in COVID-19 infection due to its pleiotropic effects with favorable renin–angiotensin–aldosterone system (RAAS) and ACE2 expression, reduction in transmembrane serine protease 2 (TMPRSS2) activity and antiandrogenic action, and therefore it may prove to act as additional protection for patients at highest risk of severe pneumonia. Future prospective clinical trials are warranted to evaluate its therapeutic potential.

24 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMiłosz Parczewski
Miłosz Parczewski
MLMagdalena Leszczyszyn-Pynka
Magdalena Leszczyszyn-Pynka
MWMagdalena Witak-Jędra
Magdalena Witak-Jędra
BSBartosz Szetela
Bartosz Szetela
JGJacek Gąsiorowski
Jacek Gąsiorowski
AUAnna Urbańska
Anna Urbańska
Reconstruction of HIV transmission links allows to trace the spread and dynamics of infection and guide epidemiological interventions. The aim of this study was to characterize transmission networks among subtype B infected patients from Poland. Maximum likelihood phylogenenetic trees were inferred from 966 HIV-1 subtype B protease/reverse transcriptase sequences from patients followed up in nine Polish HIV centers. Monophyletic clusters were identified using 3% within-cluster distance and 0.9 bootstrap values. Interregional links for the clusters were investigated and time from infection to onward transmission estimated using Bayesian dated MCMC phylogeny. Three hundred twenty one (33.2%) sequences formed 109 clusters, including ten clusters of ≥5 sequences (n = 81, 8.4%). Transmission networks were more common among MSM (234 sequences, 68.6%) compared to other infection routes (injection drug use: 28 (8.2%) and heterosexual transmissions: 59 (17.3%) cases, respectively [OR:3.5 (95%CI:2.6–4.6),p<0.001]. Frequency of clustering increased from 26.92% in 2009 to 50.6% in 2014 [OR:1.18 (95%CI:1.06–1.31),p = 0.0026; slope +2.8%/year] with median time to onward transmission within clusters of 1.38 (IQR:0.59–2.52) years. In multivariate models clustering was associated with both MSM transmission route [OR:2.24 (95%CI:1.38–3.65),p<0.001] and asymptomatic stage of HIV infection [OR:1.93 (95%CI:1.4–2.64),p<0.0001]. Additionally, interregional networks were linked to MSM transmissions [OR:4.7 (95%CI:2.55–8.96),p<0.001]. Reconstruction of the HIV-1 subtype B transmission patterns reveals increasing degree of clustering and existence of interregional networks among Polish MSM. Dated phylogeny confirms the association between onward transmission and recent infections. High transmission dynamics among Polish MSM emphasizes the necessity for active testing and early treatment in this group.